Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience

• मुख्य लेखकों: Chao Li (लेखक), ChengXin Deng (लेखक), Ping Wu (लेखक), KaiFan Liu (लेखक), Xin Huang (लेखक), MingMin Li (लेखक), XiaoMei Chen (लेखक), SuXia Geng (लेखक), PeiLong Lai (लेखक), JianYu Weng (लेखक), Xin Du (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2024-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax (Vene) with hypomethylating agents (HMAs). The study's findings show promise: the HMAs plu...